Elucida Oncology, Inc.
Biotechnology ResearchView the employees at
Elucida Oncology, Inc.-
Yongchan Lee Research Scientist
-
Princeton Junction, New Jersey, United States
-
Top 5%
Gregory Adams Chief Scientific Officer at Elucida Oncology, Inc.-
Rising Star
Feng Chen Director of Internal Platform Development at Elucida Oncology-
Monmouth Junction, New Jersey, United States
-
Rising Star
Eliel Bayever Chief Medical Officer at Elucida Oncology, Inc.-
Monmouth Junction, New Jersey, United States
-
Top 10%
Overview
Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle C’Dot drug conjugate (CDC) platform. CDCs are designed to penetrate deeper into tumors and deliver a significantly higher payload compared to antibody drug conjugates (ADCs). This combined with greater avidity for the target antigen, longer retention in tumors with minimal systemic exposure due to rapid renal clearance confers unique Target or Clear® properties. In preclinical studies, this has resulted in enhanced efficacy irrespective of antigen expression levels with reduced off-target toxicity, thereby potentially addressing the limitations of ADCs and other novel drug carriers.
-